PIII vs. AIRS, LFMD, SERA, CORBF, BDSX, QIPT, EUDA, BNR, TOI, and XGN
Should you be buying P3 Health Partners stock or one of its competitors? The main competitors of P3 Health Partners include AirSculpt Technologies (AIRS), LifeMD (LFMD), Sera Prognostics (SERA), Global Cord Blood (CORBF), Biodesix (BDSX), Quipt Home Medical (QIPT), EUDA Health (EUDA), Burning Rock Biotech (BNR), Oncology Institute (TOI), and Exagen (XGN). These companies are all part of the "healthcare" industry.
P3 Health Partners vs.
P3 Health Partners (NASDAQ:PIII) and AirSculpt Technologies (NASDAQ:AIRS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, community ranking, valuation and risk.
In the previous week, P3 Health Partners had 1 more articles in the media than AirSculpt Technologies. MarketBeat recorded 2 mentions for P3 Health Partners and 1 mentions for AirSculpt Technologies. P3 Health Partners' average media sentiment score of 1.30 beat AirSculpt Technologies' score of -0.50 indicating that P3 Health Partners is being referred to more favorably in the media.
7.8% of P3 Health Partners shares are held by institutional investors. Comparatively, 91.5% of AirSculpt Technologies shares are held by institutional investors. 17.9% of P3 Health Partners shares are held by insiders. Comparatively, 78.8% of AirSculpt Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
AirSculpt Technologies has lower revenue, but higher earnings than P3 Health Partners. AirSculpt Technologies is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.
AirSculpt Technologies has a net margin of -4.13% compared to P3 Health Partners' net margin of -6.95%. AirSculpt Technologies' return on equity of 2.22% beat P3 Health Partners' return on equity.
P3 Health Partners has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, AirSculpt Technologies has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500.
P3 Health Partners presently has a consensus target price of $2.38, suggesting a potential upside of 1,200.66%. AirSculpt Technologies has a consensus target price of $5.00, suggesting a potential upside of 50.60%. Given P3 Health Partners' stronger consensus rating and higher possible upside, analysts plainly believe P3 Health Partners is more favorable than AirSculpt Technologies.
AirSculpt Technologies received 7 more outperform votes than P3 Health Partners when rated by MarketBeat users. Likewise, 36.67% of users gave AirSculpt Technologies an outperform vote while only 26.67% of users gave P3 Health Partners an outperform vote.
Summary
AirSculpt Technologies beats P3 Health Partners on 11 of the 18 factors compared between the two stocks.
Get P3 Health Partners News Delivered to You Automatically
Sign up to receive the latest news and ratings for PIII and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
P3 Health Partners Competitors List
Related Companies and Tools
This page (NASDAQ:PIII) was last updated on 3/11/2025 by MarketBeat.com Staff
Free PIII Stock Alerts